4-MeO-PCP

PCP-class compounds produce cardiovascular stress via sympathomimetic effects. Individuals with pre-existing cardiovascular conditions (hypertension, coronary artery disease, arrhythmias) face elevated risk.

NMDA receptor antagonism may lower seizure threshold. Individuals with epilepsy or seizure disorders face elevated risk of breakthrough seizures.

4-MeO-PCP acts at the PCP binding site on the NMDA receptor — the same mechanism underlying the glutamate hypothesis of schizophrenia. Individuals with psychotic disorders or family history of psychosis are at high risk for prolonged psychotic episodes.

Mania has been reported with 3-MeO-PCP use. While community reports suggest 4-MeO-PCP is less maniacal, the shared pharmacological mechanism warrants caution in individuals with bipolar disorder.

Metabolism via multiple polymorphic CYP enzymes means hepatic impairment can substantially increase drug exposure. CYP2D6 poor metabolizers may be particularly affected.

Renal impairment reduces metabolite clearance and increases vulnerability to rhabdomyolysis-induced acute kidney injury, a documented PCP-class complication.

No reproductive toxicity data exist for 4-MeO-PCP. NMDA receptor involvement in neurodevelopment warrants absolute precautionary contraindication during pregnancy.

4-MeO-PCP displays appreciable SERT affinity (Roth et al. 2013). Co-administration with serotonergic medications poses risk of serotonin syndrome. The published fatality involved venlafaxine co-ingestion, though interaction contribution was not quantified.